Health Condition 1: E11- Type 2 diabetes mellitus
Conditions
Interventions
Intervention1: Empagliflozin 25mg OD for 20 weeks: Empagliflozin 25mg OD for 20 weeks
Control Intervention1: Dapagliflozin 5mg OD: Dapagliflozin 5mg OD
Sponsors
Dr Manu Arya
Eligibility
Inclusion criteria
Inclusion criteria: All Patients with Type2 diabetes mellitus as per ADA guidelines Patients of either gender with age more than 18 years. Patients giving written informed consent.
Exclusion criteria
Exclusion criteria: Pregnant & lactating women. Patients not complying with the study protocol. Patients with underlying comorbid conditions like recurrent UTI, chronic renal diseases. Patients with co-morbid conditions like malignancy, psychiatric disorders, substance abuse Patients with concomitant medications likely to interfere with glycemic control e.g.: Steroids, Beta-blockers, Thiazide Diuretics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting Plasma Glucose(FPG), glycosylated haemoglobin(HbA1c), NT-pro BNP , Kidney function Test(KFT) Timepoint: Fasting Plasma Glucose(FPG), glycosylated haemoglobin(HbA1c), NT-pro BNP , Kidney function Test(KFT) follow up after 4 weeks and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug monitoring using a pre-validated ADR checklist along with spontaneous reporting Timepoint: Changes in NT-proBNP, KFT & FPG from baseline to End of the study follow up after 4 weeks & 8 weeks | — |
Countries
India
Contacts
Public ContactDr Manu Arya
Teerthanker Mahaveer University Medical College and Research Centre
Outcome results
None listed